ƒAƒgƒs[«”畆‰Š ‹γB‘εŠwˆγŠw•””畆‰ΘŠw‹³ŽΊTOP‚Φ
‡•ΉΗ
ƒAƒgƒs[«”畆‰Š‚ΖƒEƒBƒ‹ƒXŠ΄υΗ ƒAƒgƒs[«”畆‰Š‚ΖΧ‹ΫŠ΄υΗ ƒAƒgƒs[«”畆‰Š‚Ζ”’“ΰα
[μCŽi1)AˆΐŒ³Tˆκ˜Y2)AŒ¦μ’ΌŽq3)A–쐣‘P–Ύ4)AŒΓ]‘—²1)
1j‹γB‘εŠw‘εŠw‰@ˆγŠwŒ€‹†‰@”畆‰ΘA2j‹v—―•Δ‘εŠwˆγŠw•””畆‰ΘA3j‹γB‘εŠw•a‰@ˆγ—Ïξ•ρ•”A4j‹γB‘εŠw‘εŠw‰@ˆγŠwŒ€‹†‰@ˆγ—Ïξ•ρ•”
ƒAƒgƒs[«”畆‰Š‚ΖΧ‹ΫŠ΄υΗ
—vŽ| ‚Ν‚Ά‚ί‚Ι Œ€‹†–Ϊ“I •ϋ–@ Œ‹‰Κ lŽ@ Œ‹˜_ ŽQl•ΆŒ£
‡•ΉΗ•]‰Ώ•\ˆκ——
•]‰Ώ•\‚ΜŒ©•ϋ
•]‰Ώ–@‚ΜŒ©•ϋ
ŽQl•ΆŒ£
1) McCormick A, Fleming D, Charlton J. Morbidity statistics from general practice. Fourth national study 1991-1992. London: HMSO, 1995.
2) Bruijnzeels MA, van Suijlekom-Smit LWA, van der Velden J, van der Wouden JC. The child in general practice. Rotterdam/Utrecht: Erasmus Universiteit/NIVEL, 1993.
3) Van der Ven-Daane I, Bruijnzeels MA, van der Wouden JC, van Suijlekom-Smit LWA. Occurrence and treatment of impetigo vulgaris in children. Huisarts Wet 1993; 36: 291-3.
4) Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 1992; 36(2): 287-90.
5) Koning S, van Suijlekom-Smit LW, Nouwen JL, Verduin CM, Bernsen RM, Oranje AP, Thomas S, van der Wouden JC. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomized placebo controlled trial. BMJ. 2002; 324: 203-6.
6) Feder HM Jr, Abrahamian LM, Grant-Kels JM. Is penicillin still the drug of choice for non-bullous impetigo? Lancet. 1991; 338: 803-5.
7) Dagan R. Impetigo in childhood: changing epidemiology and new treatments. Pediatr Ann. 1993; 22: 235-40.
8) Skin diseases. In: Collier JAB, Longmore JM, HOdgetts(eds). Oxford handbook of clinical specialities. Fourth edition. Oxford: OUP, 1997; 573-603.
9) Infections. In: Hunter JAA, Savin JA, Dahl MV.(eds). Clinical dermatology. Second edition. Oxford: Blackwell Science, 1995; 161-93.
10) Hay RJ, Adriaans BM. Bacterial infections. In: Chapman RH, Burton JL, Burns DA, Breathnach SM(eds). Rook/Wilkinson/Ebling Textbook of dermatology. Six edition. Oxford: Blackwell Science, 1998; 1097-1179.
11) British Medical Association & Royal Pharmaceutical Society of Great Britain. Anti-bacterial drugs(5.1). In: British National Formulary. Issue 41. London: BMJ books, 2001; 252-90.
12) Jaffe GV, Grimshaw JJ. A clinical trial of hydrocortisone/potassium hydroxyquinoline sulphate ('Quinocort') in the treatment of infected eczema and impetigo in general practice. Pharmatherapeutica. 1986; 4: 628-36.
13) Nolting S, Strauss WB. Treatment of impetigo and ecthyma. A comparison of sulconazole with miconazole. Int J Dermatol. 1988; 27: 716-9.
14) Ruby RJ, Nelson JD. The influence of hexachlorophene scrubs on the response to placebo or penicillin therapy in impetigo. Pediatrics. 1973; 52(6): 854-9.
15) Sharquie KE, al-Turfi IA, al-Salloum SM. The antibacterial activity of tea in vitro and in vivo (in patients with impetigo contagiosa). J Dermatol. 2000; 27(11): 706-10.
16) Sewell DL. Bacteriology. In: McClatchey KD(ed). Clinical laboratory medicine. Baltimore: Williams and Wilkins, 1994; 1111-68.
17) Eells LD, Mertz PM, Piovanetti Y, Pekoe GM, Eaglstein WH. Topical antibiotic treatment of impetigo with mupirocin. Arch Dermatol. 1986; 122(11): 1273-6.
18) Zaynoun ST, Matta MT, Uwayda MM, Kurban AK. Topical antibiotics in pyodermas. Br J Dermatol. 1974; 90(3): 331-4.
19) Bass JW, Chan DS, Creamer KM, Thompson MW, Malone FJ, Becker TM, Marks SN. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J. 1997; 16(7): 708-10.
20) Britton JW, Fajardo JE, Krafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr. 1990; 117(5): 827-9.
21) Koranyi KI, Burech DL, Haynes RE. Evaluation of bacitracin ointment in the treatment of impetigo. Ohio State Med J. 1976; 72(6): 368-70.
22) George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003 Jun;53(491):480-7.
23) Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol. 1989; 20(6): 1083-7.
24) Morley PA, Munot LD. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr Med Res Opin. 1988; 11(2): 142-8.
25) Sutton JB. Efficacy and acceptability of fusidic acid cream and mupirocin ointment in facial impetigo. Curr Ther Res 1992; 51: 673-8.
26) White DG, Collins PO, Rowsell RB. Topical antibiotics in the treatment of superficial skin infections in general practice--a comparison of mupirocin with sodium fusidate. J Infect. 1989; 18(3): 221-9.
27) Jaffe AC, OfBrien CA, Reed MD, Blumer JL. Randomized comparative evaluation of augmentin® and cefaclor in pediatric skin and soft tissue infections. Curr Ther Res 1985; 38: 160-8.
28) Demidovich CW, Wittler RR, Ruff ME, Bass JW, Browning WC. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child. 1990; 144(12): 1313-5.
29) McVicar J. Towards evidence based emergency medicine: best BETS from the Manchester Royal Infirmary. Oral or topical antibiotics for impetigo. J Accid Emerg Med. 1999; 16(5): 364-5.
30) Stringel G, Bawdon R, Savrich M, Guertin L, Horton J. Topical and systemic antibiotics in the prevention of wound infection. J Pediatr Surg. 1989; 24(10): 1003-6.
31) Bareggi SR, Pirola R, De Benedittis G. Skin and plasma levels of acetylsalicylic acid: a comparison between topical aspirin/diethyl ether mixture and oral aspirin in acute herpes zoster and postherpetic neuralgia. Eur J Clin Pharmacol. 1998; 54(3): 231-5.
ƒgƒbƒvƒy[ƒW‚Φ–ί‚ι γ‚Φ–ί‚ι
‹γB‘εŠwˆγŠw•””畆‰ΘŠw‹³ŽΊTOP‚Φ